Global Pulmonary Drug Delivery Systems Market 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Product Type
08. MDIs
08.1 Introduction
08.2 Basic Components
08.3 Drug Deposition
08.4 Pros and Cons of MDIs
08.5 Market Size and Forecast
09. DPIs
09.1 Introduction
09.2 Segmentation
09.3 Basic Components
09.4 Drug Delivery
09.5 Drug Deposition
09.6 Pros and Cons of DPIs
09.7 Market Size and Forecast
10. Nebulizers
10.1 Introduction
10.2 Pros and Cons of Nebulizers
10.3 Segmentation
10.4 Jet Nebulizers
10.5 Ultrasonic Nebulizers
10.6 Market Size and Forecast
11. Geographical Segmentation
11.1 Pulmonary Drug Delivery Systems Market in Americas
11.1.1 Market Size and Forecast
11.2 Pulmonary Drug Delivery Systems Market in EMEA Region
11.2.1 Market Size and Forecast
11.3 Pulmonary Drug Delivery Systems Market in APAC Region
11.3.1 Market Size and Forecast
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 AstraZeneca
19.2.2 Boehringer Ingelheim
19.2.3 GlaxoSmithKline
19.2.4 Novartis
19.2.5 Philips Healthcare
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 AstraZeneca plc
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue 2013
20.1.4 Business Segmentation by Revenue 2011-2013
20.1.5 Sales by Geography
20.1.6 Business Strategy
20.1.7 Key Developments
20.1.8 SWOT Analysis
20.2 Boehringer Ingelheim
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue 2013
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Geographical Segmentation by Revenue 2013
20.2.6 Business Strategy
20.2.7 Recent Developments
20.2.8 SWOT Analysis
20.3 GlaxoSmithKline
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation
20.3.4 Business Segmentation by Revenue 2012 and 2013
20.3.5 Sales by Geography
20.3.6 Pipeline Products
20.3.7 Business Strategy
20.3.8 Key Information
20.3.9 SWOT Analysis
20.4 Novartis
20.4.1 Key Facts
20.4.2 Business Description
20.4.3 Business Segmentation
20.4.4 Revenue by Business Segmentation
20.4.5 Revenue Comparison 2012 and 2013
20.4.6 Sales by Geography
20.4.7 Business Strategy
20.4.8 Key Developments
20.4.9 SWOT Analysis
20.5 Philips Healthcare
20.5.1 Key Facts
20.5.2 Business Overview
20.5.3 Revenue by Business Segmentation 2012
20.5.4 Sales by Geography
20.5.5 Business Strategy
20.5.6 Key Developments
20.5.7 SWOT Analysis
21. Other Reports in this Series